Skip to main content
KTTA
NASDAQ Life Sciences

10% Holder Coastlands Buys $806K of Pasithea Stock Over Three Sessions

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.434
Mkt Cap
$15.962M
52W Low
$0.281
52W High
$2.06
52W Position info
55% above low
Off High info
79% below high
Rel. Volume info
3.0× avg
Market data snapshot near publication time

KTTA sits 55% above its 52-week low of $0.281 on elevated volume (3.0× avg).

Summary

Coastlands Capital LP bought 1,667,514 Pasithea shares for $805,944 in open-market trades from November 13-17, raising its position to 5,502,549 shares just after positive PAS-004 efficacy data.


Key Events · Ownership and Investor Activity · KTTA

  • 10% Holder Adds 1.67M Shares

    Coastlands Capital LP acquired 1,667,514 shares for $805,944.11 in three open-market purchases between 2026-11-13 and 2026-11-17.

  • Stake Grows to 5.5M Shares

    Post-transaction holdings reached 5,502,549 shares, all held indirectly through Coastlands Capital LP.

  • Purchases Priced $0.47-$0.50

    The three tranches were 209,431 shares at $0.4956, 583,083 at $0.4989 and 875,000 at $0.4700 — all above today's $0.4343 quote.

  • Timed to Positive PAS-004 Data

    Buying followed the 2026-11-13 release of the first efficacy data for oral PAS-004 in NF1 patients and the 2026-11-03 FDA IND clearance.


Analysis · KTTA · Life Sciences

Coastlands Capital LP put $805,944 of real money into Pasithea across three open-market purchases from November 13 to November 17, lifting its stake to 5,502,549 shares. For a company this size, that is a large commitment, and it lands right after the November 13 release of the first actual efficacy data for oral PAS-004 in NF1 patients and the November 3 FDA IND clearance. The buyer is a financial investor, not an operator, so this is a conviction bet on the data rather than a management signal — but the size and the fact that it was done at market, not through an option exercise, makes it the strongest ownership-side endorsement the stock has seen this quarter.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KTTA was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16M. The 52-week trading range was $0.28 to $2.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KTTA - Latest Insights

KTTA
Nov 13, 2026, 5:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.479
Real-time Price: $0.4343 info
Change: -$0.0447 (-9%) info
Market Cap: $15.962M info
KTTA
Nov 13, 2026, 2:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.510
Real-time Price: $0.4343 info
Change: -$0.0757 (-15%) info
Market Cap: $15.962M info
KTTA
Nov 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3591
Real-time Price: $0.4343 info
Change: +$0.0752 (+21%) info
Market Cap: $15.962M info
KTTA
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.550
Real-time Price: $0.4343 info
Change: -$0.1157 (-21%) info
Market Cap: $15.962M info
KTTA
Sep 09, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5697
Real-time Price: $0.4343 info
Change: -$0.1354 (-24%) info
Market Cap: $15.962M info